Gene chip technology may identify life-threatening blood infection
Right now there’s no rapid way to diagnose sepsis, a fast-moving blood infection that is a leading cause of death in hospital intensive care units. Doctors who suspect sepsis typically rush to prescribe powerful antibiotics, but this can lead to the inappropriate treatment of patients with uncontrollable inflammation without an underlying infection. New research at the School of Medicine suggests that doctors one day could quickly distinguish sepsis from widespread non-infectious inflammation based on genetic profiles of patients’ blood.
Gene chip technology shows potential for identifying life-threatening blood infection
Right now there’s no rapid way to diagnose sepsis, a fast-moving blood infection that is a leading cause of death in hospital intensive care units. Doctors who suspect sepsis typically rush to prescribe powerful antibiotics, but this can lead to the inappropriate treatment of patients with uncontrollable inflammation without an underlying infection. New research at Washington University School of Medicine in St. Louis suggests that doctors one day could quickly distinguish sepsis from widespread non-infectious inflammation based on genetic profiles of patients’ blood.
Detection of breast cancer recurrence possible with simple blood test
Detecting breast cancer recurrence with a simple blood testPhysicians treating women with breast cancer recognize the need for a specific and sensitive method to monitor disease recurrence, so they should be encouraged by a new study that describes a biomarker that seems to fill those criteria. Researchers at the School of Medicine have shown that mammaglobin, a protein secreted by breast tumor cells, can readily be detected in the blood serum of patients with metastatic breast cancer using an inexpensive, reliable clinical test.
Detection of breast cancer recurrence possible with simple blood test
Detecting breast cancer recurrence with a simple blood test.Physicians treating women with breast cancer recognize the need for a specific and sensitive method to monitor disease recurrence, so they should be encouraged by a new study that describes a biomarker that seems to fill those criteria. Researchers at Washington University School of Medicine in St. Louis have shown that mammaglobin, a protein secreted by breast tumor cells, can readily be detected in the blood serum of patients with metastatic breast cancer using an inexpensive, reliable clinical test.